Remimazolam versus propofol sedation on the quality of recovery after colonoscopy: A randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200066689

Enrollment

Unknown

Registered

2022-12-13

Start date

2022-12-17

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Remimazolam group:Sufentanil combined with Remazolam for sedation

Propofol group:Sufentanil combined with propofol for sedation

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1). elective outpatients colonoscopy; 2). American Society of Anesthesiologists (ASA) 1 to 3; 3). Aged > 65 years

Exclusion criteria

Exclusion criteria: 1)patient refusal to participate. 2) BMI greater than 30; 3) allergic or contraindication to study drugs; 4) inability to ambulate without assistance; 5) Required therapeutic endoscopies, such as endoscopic mucosal resection or endoscopic submucosal dissection; 6)history of medication or alcohol abuse 7)any other conditions that precluded study inclusion, such as cognitive impairment, history of psychiatric illness, history of neurological disease, or inability to communicate in Mandarin Chinese.

Design outcomes

Primary

Measure	Time frame
the incidence of recovery in the cognitive domain of the PostopQRS on day 3 after colonoscopy;	—

Secondary

Measure	Time frame
Induction time;Recovery time;Incidence of hypotension;Incidence of hypoxemia;Time to discharge;Postoperative quality of recovery;Endoscopist satisfaction;Patient satisfaction;Patient satisfaction;Injection pain;	—

Countries

China

Contacts

Public ContactYusheng Yao

Fujian Provincial Hospital

fjslyys@126.com13559939629

Outcome results